

Is Lupus Anticoagulant a Significant Feature of COVID-Literature

Seminars in Thrombosis and Hemostasis

48, 055-071

DOI: [10.1055/s-0041-1729856](https://doi.org/10.1055/s-0041-1729856)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Laboratory testing for suspected COVID-19 vaccine-induced (immune) thrombotic thrombocytopenia. International Journal of Laboratory Hematology, 2021, 43, 559-570.	1.3	66
2	COVID-19 and Antiphospholipid Antibodies: Time for a Reality Check?. Seminars in Thrombosis and Hemostasis, 2022, 48, 072-092.	2.7	44
3	The Impact of SARS-CoV-2 Infection on Blood Coagulation and Fibrinolytic Pathways: A Review of Prothrombotic Changes Caused by COVID-19. Seminars in Thrombosis and Hemostasis, 2022, 48, 019-030.	2.7	17
4	COVID-19 coagulopathies: Human blood proteins mimic SARS-CoV-2 virus, vaccine proteins and bacterial co-infections inducing autoimmunity. BioEssays, 2021, 43, e2100158.	2.5	17
5	What We Know (and Do not Know) Regarding the Pathogenesis of Pulmonary Thrombosis in COVID-19. Seminars in Thrombosis and Hemostasis, 2023, 49, 027-033.	2.7	10
6	Maintaining Hemostasis and Preventing Thrombosis in Coronavirus Disease 2019 (COVID-19)â€”Part III. Seminars in Thrombosis and Hemostasis, 2022, 48, 003-007.	2.7	14
7	Anesthesia and intensive care for patients with COVID-19. Russian Federation of anesthesiologists and reanimatologists guidelines. Alexander Saltanov Intensive Care Herald, 2022, , 5-140.	1.0	7
8	COVID-19 Induced Coagulopathy (CIC): Thrombotic Manifestations of Viral Infection. TH Open, 2022, 06, e70-e79.	1.4	4
9	The Benefits of Heparin Use in COVID-19: Pleiotropic Antiviral Activity beyond Anticoagulant and Anti-Inflammatory Properties. Seminars in Thrombosis and Hemostasis, 2022, , .	2.7	11
10	To Anticoagulate or Not to Anticoagulate in COVID-19: Lessons after 2 Years. Seminars in Thrombosis and Hemostasis, 2023, 49, 062-072.	2.7	13
11	Intracranial complications of hypercoagulability and superinfection in the setting of COVID-19: illustrative cases. Journal of Neurosurgery Case Lessons, 2022, 3, .	0.3	5
12	Association of Lupus Anticoagulant status with Disease Course in SARS-CoV-2 (COVID-19) Infection. Clinical and Applied Thrombosis/Hemostasis, 2022, 28, 107602962211272.	1.7	1
13	Complementary Sets of Autoantibodies Induced by SARS-CoV-2, Adenovirus and Bacterial Antigens Cross-React with Human Blood Protein Antigens in COVID-19 Coagulopathies. International Journal of Molecular Sciences, 2022, 23, 11500.	4.1	6
14	COVID-19 and antiphospholipid antibodies. Best Practice and Research in Clinical Haematology, 2022, 35, 101402.	1.7	12
15	Antiphospholipid Syndrome in COVID-19: Contribution of the Follow-up of Antiphospholipid Autoantibodies. Seminars in Thrombosis and Hemostasis, 2023, 49, 097-102.	2.7	3
16	Autoimmune Diseases Affecting Hemostasis: A Narrative Review. International Journal of Molecular Sciences, 2022, 23, 14715.	4.1	7
17	Microorganisms in the Pathogenesis and Management of Anti-phospholipid Syndrome (Hughes) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 10		
18	Maintaining Hemostasis and Preventing Thrombosis in Coronavirus Disease 2019 (COVID-19)â€”Part IV. Seminars in Thrombosis and Hemostasis, 2023, 49, 003-008.	2.7	9

#	ARTICLE	IF	CITATIONS
19	Editorial Compilation XIII. Seminars in Thrombosis and Hemostasis, 0, , .	2.7	0
20	Association between Severe Acute Respiratory Syndrome Coronavirus 2 Infection (Coronavirus) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Assessment. Seminars in Thrombosis and Hemostasis, 2023, 49, 558-560.	2.7	3
21	2023 Eberhard F. Mammen Award Announcements: Part lâ€™Most Popular Articles. Seminars in Thrombosis and Hemostasis, 2023, 49, 417-426.	2.7	3
22	Antiphospholipid antibodies in convalescent plasma of donors recovered from mild <scp>COVID</scp> â€19 infection. Vox Sanguinis, 0, , .	1.5	0
23	An Overview of Laboratory Testing for Antiphospholipid Antibodies. Methods in Molecular Biology, 2023, , 253-262.	0.9	0
24	Antiphospholipid Antibodies Occurrence in Acute SARS-CoV-2 Infection without Overt Thrombosis. Biomedicines, 2023, 11, 1241.	3.2	1
25	Vascular risk factors for COVID-19 ARDS: endothelium, contact-kinin system. Frontiers in Medicine, 0, 10, .	2.6	0
26	Are Antiphospholipid Antibodies a Surrogate Risk Factor for Thrombosis in Sepsis?. Seminars in Thrombosis and Hemostasis, 2024, 50, 284-287.	2.7	0
27	Thrombosis and Hyperinflammation in COVID-19 Acute Phase Are Related to Anti-Phosphatidylserine and Anti-Phosphatidylinositol Antibody Positivity. Biomedicines, 2023, 11, 2301.	3.2	3
28	Editorial Compilation XIV. Seminars in Thrombosis and Hemostasis, 0, , .	2.7	0
29	Thromboâ€inflammatory response in hospitalized patients with <scp>COVID</scp> â€19; a single institution experience. Internal Medicine Journal, 0, , .	0.8	0
30	Risk Factors for Antiphospholipid Antibodies and Antiphospholipid Syndrome. Seminars in Thrombosis and Hemostasis, 0, , .	2.7	0
31	2024 Eberhard F. Mammen Award Announcements: Part lâ€™Most Popular Articles. Seminars in Thrombosis and Hemostasis, 0, , .	2.7	0